David J Harrison

List of Publications by Year
in descending order

203 papers	12,270 citations	38720 50 h-index	29127 104 g-index
206 all docs	206 docs citations	206 times ranked	20930 citing authors

#	Article	IF	Citations
1	Tissue Proteomic Analysis Identifies Mechanisms and Stages of Immunopathology in Fatal COVID-19. American Journal of Respiratory Cell and Molecular Biology, 2022, 66, 196-205.	1.4	26
2	Collateral-resistance to estrogen and HER-activated growth is associated with modified AKT, ERÎ±, and cell-cycle signaling in a breast cancer model. Exploration of Targeted Anti-tumor Therapy, 2022, 3, 97-116.	0.5	0
3	Code of practice needed for samples donated by trial participants. Lancet Oncology, The, 2022, 23, e89-e90.	5.1	4
4	Believe the HiPe: Hierarchical perturbation for fast, robust, and model-agnostic saliency mapping. Pattern Recognition, 2022, 129, 108743.	5.1	12
5	The renal lineage factor PAX8 controls oncogenic signalling in kidney cancer. Nature, 2022, 606, 999-1006.	13.7	24
6	Tissue-Specific Immunopathology in Fatal COVID-19. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 192-201.	2.5	243
7	Recommendations for cellular and molecular pathology input into clinical trials: a systematic review and metaâ€aggregation. Journal of Pathology: Clinical Research, 2021, 7, 191-202.	1.3	4
8	A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian Cancer. Clinical Cancer Research, 2021, 27, 3028-3038.	3.2	4
9	Automated Detection and Classification of Desmoplastic Reaction at the Colorectal Tumour Front Using Deep Learning. Cancers, 2021, 13, 1615.	1.7	8
10	Assessment of Immunological Features in Muscle-Invasive Bladder Cancer Prognosis Using Ensemble Learning. Cancers, 2021, 13, 1624.	1.7	17
11	YAP Translocation Precedes Cytoskeletal Rearrangement in Podocyte Stress Response: A Podometric Investigation of Diabetic Nephropathy. Frontiers in Physiology, 2021, 12, 625762.	1.3	2
12	Abstract CT140: NUC-3373, a targeted inhibitor of thymidylate synthase, in patients with advanced colorectal cancer. Cancer Research, 2021, 81, CT140-CT140.	0.4	1
13	Abstract 931: From bench to bedside: Using ProTide chemistry to transform 3'-deoxyadenosine into the novel anti-cancer agent Nuc-7738. , 2021, , .		1
14	The modification of cancer risk by chemicals. Toxicology Research, 2021, 10, 800-809.	0.9	2
15	The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial. Clinical Cancer Research, 2021, 27, 6500-6513.	3.2	16
16	Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension. Lancet Oncology, The, 2021, 22, e435-e445.	5.1	13
17	Genetic mechanisms of critical illness in COVID-19. Nature, 2021, 591, 92-98.	13.7	1,014
18	The differential expression of micro-RNAs 21, 200c, 204, 205, and 211 in benign, dysplastic and malignant melanocytic lesions and critical evaluation of their role as diagnostic biomarkers. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 121-130.	1.4	5

#	Article	IF	Citations
19	The Efficacy of Sunitinib Treatment of Renal Cancer Cells Is Associated with the Protein PHAX In Vitro. Biology, 2020, 9, 74.	1.3	2
20	Spatial immune profiling of the colorectal tumor microenvironment predicts good outcome in stage II patients. Npj Digital Medicine, 2020, 3, 71.	5.7	41
21	Computerized Image Analysis of Tumor Cell Nuclear Morphology Can Improve Patient Selection for Clinical Trials in Localized Clear Cell Renal Cell Carcinoma. Journal of Pathology Informatics, 2020, 11, 35.	0.8	2
22	The landscape of genomic copy number alterations in colorectal cancer and their consequences on gene expression levels and disease outcome. Molecular Aspects of Medicine, 2019, 69, 48-61.	2.7	40
23	Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031. Scientific Reports, 2019, 9, 7643.	1.6	12
24	Automated Analysis of Lymphocytic Infiltration, Tumor Budding, and Their Spatial Relationship Improves Prognostic Accuracy in Colorectal Cancer. Cancer Immunology Research, 2019, 7, 609-620.	1.6	69
25	Automated tumour budding quantification by machine learning augments TNM staging in muscle-invasive bladder cancer prognosis. Scientific Reports, 2019, 9, 5174.	1.6	33
26	Evaluation of the dual mTOR/PI3K inhibitors Gedatolisib (PF-05212384) and PF-04691502 against ovarian cancer xenograft models. Scientific Reports, 2019, 9, 18742.	1.6	18
27	Novel Internationally Verified Method Reports Desmoplastic Reaction as the Most Significant Prognostic Feature For Disease-specific Survival in Stage II Colorectal Cancer. American Journal of Surgical Pathology, 2019, 43, 1239-1248.	2.1	35
28	Identifying prognostic structural features in tissue sections of colon cancer patients using point pattern analysis. Statistics in Medicine, 2019, 38, 1421-1441.	0.8	6
29	Raman spectroscopy investigation of biochemical changes in tumor spheroids with aging and after treatment with staurosporine. Journal of Biophotonics, 2019, 12, e201800201.	1.1	6
30	Experimental Nonalcoholic Steatohepatitis and Liver Fibrosis AreÂAmeliorated by Pharmacologic Activation of Nrf2 (NF-E2 p45-Related Factor 2). Cellular and Molecular Gastroenterology and Hepatology, 2018, 5, 367-398.	2.3	154
31	Acquired and Intrinsic Resistance to Colorectal Cancer Treatment. , 2018, , .		6
32	A principled machine learning framework improves accuracy of stage II colorectal cancer prognosis. Npj Digital Medicine, 2018, 1, 52.	5.7	47
33	Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme. ESMO Open, 2018, 3, e000408.	2.0	4
34	Podocyte injury elicits loss and recovery of cellular forces. Science Advances, 2018, 4, eaap8030.	4.7	17
35	WHO/ISUP classification, grading and pathological staging of renal cell carcinoma: standards and controversies. World Journal of Urology, 2018, 36, 1913-1926.	1.2	146
36	Epigenetic sampling effects: nephrectomy modifies the clear cell renal cell cancer methylome. Cellular Oncology (Dordrecht), 2017, 40, 293-297.	2.1	2

#	Article	IF	Citations
37	A systematic search strategy identifies cubilin as independent prognostic marker for renal cell carcinoma. BMC Cancer, 2017, 17, 9.	1.1	27
38	Overcoming intratumoural heterogeneity for reproducible molecular risk stratification: a case study in advanced kidney cancer. BMC Medicine, 2017, 15, 118.	2.3	8
39	Kinetic modelling of in vitro data of PI3K, mTOR1, PTEN enzymes and on-target inhibitors Rapamycin, BEZ235, and LY294002. European Journal of Pharmaceutical Sciences, 2017, 97, 170-181.	1.9	4
40	Inhibition of pH regulation as a therapeutic strategy in hypoxic human breast cancer cells. Oncotarget, 2017, 8, 42857-42875.	0.8	62
41	A signaling visualization toolkit to support rational design of combination therapies and biomarker discovery: SiViT. Oncotarget, 2017, 8, 29657-29667.	0.8	2
42	Novel histopathologic feature identified through image analysis augments stage II colorectal cancer clinical reporting. Oncotarget, 2016, 7, 44381-44394.	0.8	20
43	Could molecular pathology testing in lung cancer be more cost-effective?. Journal of Clinical Pathology, 2016, 69, 938-941.	1.0	6
44	Antitumour activity of the novel flavonoid Oncamex in preclinical breast cancer models. British Journal of Cancer, 2016, 114, 905-916.	2.9	42
45	Targeted SERS nanosensors measure physicochemical gradients and free energy changes in live 3D tumor spheroids. Nanoscale, 2016, 8, 16710-16718.	2.8	23
46	Risk score predicts highâ€grade prostate cancer in DNAâ€methylation positive, histopathologically negative biopsies. Prostate, 2016, 76, 1078-1087.	1.2	74
47	Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models. BMC Cancer, 2016, 16, 205.	1.1	5
48	Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 167.e17-167.e23.	0.8	22
49	Next-Generation Pathology. Methods in Molecular Biology, 2016, 1386, 61-72.	0.4	8
50	A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells. Oncotarget, 2016, 7, 75874-75901.	0.8	27
51	The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer. Oncotarget, 2016, 7, 4695-4711.	0.8	26
52	Dynamic epigenetic changes to VHL occur with sunitinib in metastatic clear cell renal cancer. Oncotarget, 2016, 7, 25241-25250.	0.8	14
53	Study of the effect of novel anticancer agent oncamex on gene expression profiles of preclinical breast cancer models.. Journal of Clinical Oncology, 2016, 34, e14071-e14071.	0.8	0
54	Relationship between differentially expressed mRNA and mRNA-protein correlations in a xenograft model system. Scientific Reports, 2015, 5, 10775.	1.6	447

#	Article	IF	Citations
55	Novel Monte Carlo approach quantifies data assemblage utility and reveals power of integrating molecular and clinical information for cancer prognosis. Scientific Reports, 2015, 5, 15563.	1.6	0
56	Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series ofin vitrobreast cancer models. Oncotarget, 2015, 6, 24856-24870.	0.8	76
57	Translational research will fail without surgical leadership: SCOTRRCC a successful surgeon-led Nationwide translational research infrastructure in renal cancer. Journal of the Royal College of Surgeons of Edinburgh, 2015, 13, 181-186.	0.8	3
58	Validation of a Molecular and Pathological Model for Five-Year Mortality Risk in Patients with Early Stage Lung Adenocarcinoma. Journal of Thoracic Oncology, 2015, 10, 67-73.	0.5	44
59	Sunitinib Treatment Exacerbates Intratumoral Heterogeneity in Metastatic Renal Cancer. Clinical Cancer Research, 2015, 21, 4212-4223.	3.2	33
60	MBD4 Interacts With and Recruits USP7 to Heterochromatic Foci. Journal of Cellular Biochemistry, 2015, 116, 476-485.	1.2	15
61	The Development of Prognostic and Predictive Biomarkers in Renal Cell Cancer Are Not One and the Same Thing. European Urology, 2015, 67, 21-22.	0.9	1
62	Quantitative analysis of NRF2 pathway reveals key elements of the regulatory circuits underlying antioxidant response and proliferation of ovarian cancer cells. Journal of Biotechnology, 2015, 202, 12-30.	1.9	34
63	Multi-Scale Genomic, Transcriptomic and Proteomic Analysis of Colorectal Cancer Cell Lines to Identify Novel Biomarkers. PLoS ONE, 2015, 10, e0144708.	1.1	40
64	Increased STAT1 Signaling in Endocrine-Resistant Breast Cancer. PLoS ONE, 2014, 9, e94226.	1.1	28
65	Systems Analysis of Drug-Induced Receptor Tyrosine Kinase Reprogramming Following Targeted Mono- and Combination Anti-Cancer Therapy. Cells, 2014, 3, 563-591.	1.8	28
66	Customizing the Therapeutic Response of Signaling Networks to Promote Antitumor Responses by Drug Combinations. Frontiers in Oncology, 2014, 4, 13.	1.3	14
67	Multidisciplinary urological engagement in translational renal cancer research. BJU International, 2014, 114, 474-475.	1.3	2
68	Quantification of tumour budding, lymphatic vessel density and invasion through image analysis in colorectal cancer. Journal of Translational Medicine, 2014, 12, 156.	1.8	42
69	Novel flavonoids as anti-cancer agents: mechanisms of action and promise for their potential application in breast cancer. Biochemical Society Transactions, 2014, 42, 1017-1023.	1.6	58
70	The Molecular Biology of Renal Cancer: Another Piece of the Puzzle. European Urology, 2014, 66, 85-86.	0.9	4
71	Carbonic Anhydrase 9 Expression Increases with Vascular Endothelial Growth Factorâ€“Targeted Therapy and Is Predictive of Outcome in Metastatic Clear Cell Renal Cancer. European Urology, 2014, 66, 956-963.	0.9	38
72	Predicting chemotherapy response in invasive breast cancer.. Journal of Clinical Oncology, 2014, 32, 1084-1084.	0.8	0

#	Article	IF	Citations
73	Characterising the tumour morphological response to therapeutic intervention. DMM Disease Models and Mechanisms, 2013, 6, 252-60.	1.2	4
74	Predicting response to the anti-estrogen fulvestrant in recurrent ovarian cancer. Gynecologic Oncology, 2013, 131, 368-373.	0.6	22
75	The Effect of VEGF-Targeted Therapy on Biomarker Expression in Sequential Tissue from Patients with Metastatic Clear Cell Renal Cancer. Clinical Cancer Research, 2013, 19, 6924-6934.	3.2	62
76	Feedforward and feedback regulation of the MAPK and PI3K oscillatory circuit in breast cancer. Cellular Signalling, 2013, 25, 26-32.	1.7	24
77	Clinical Utility of an Epigenetic Assay to Detect Occult Prostate Cancer in Histopathologically Negative Biopsies: Results of the MATLOC Study. Journal of Urology, 2013, 189, 1110-1116.	0.2	200
78	New strategies for targeting the hypoxic tumour microenvironment in breast cancer. Cancer Treatment Reviews, 2013, 39, 171-179.	3.4	167
79	5-hydroxymethylcytosine profiling as an indicator of cellular state. Epigenomics, 2013, 5, 655-669.	1.0	52
80	TMA Navigator: network inference, patient stratification and survival analysis with tissue microarray data. Nucleic Acids Research, 2013, 41, W562-W568.	6.5	16
81	Human tissue in systems medicine. FEBS Journal, 2013, 280, 5949-5956.	2.2	10
82	The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers. Journal of Visualized Experiments, 2013, , .	0.2	8
83	Use of Microarray Analysis to Investigate EMT Gene Signatures. Methods in Molecular Biology, 2013, 1046, 85-95.	0.4	2
84	Differential Expression of Prognostic Proteomic Markers in Primary Tumour, Venous Tumour Thrombus and Metastatic Renal Cell Cancer Tissue and Correlation with Patient Outcome. PLoS ONE, 2013, 8, e60483.	1.1	30
85	Systems Pathology. , 2013, , 2097-2099.		1
86	Lactate, a product of glycolytic metabolism, inhibits histone deacetylase activity and promotes changes in gene expression. Nucleic Acids Research, 2012, 40, 4794-4803.	6.5	249
87	Editorial: [Hot Topic: Molecular Pathology in Therapeutics: Where are We Now, and Where are We Going?]. Current Drug Targets, 2012, 13, 1473-1474.	1.0	0
88	HER2 expression in ovarian carcinoma: caution and complexity in biomarker analysis. Journal of Clinical Pathology, 2012, 65, 670-671.	1.0	21
89	Tissue of origin determines cancer-associated CpG island promoter hypermethylation patterns. Genome Biology, 2012, 13, R84.	13.9	140
90	Tissue type is a major modifier of the 5-hydroxymethylcytosine content of human genes. Genome Research, 2012, 22, 467-477.	2.4	348

#	Article	IF	Citations
91	Conductive carbon tape used for support and mounting of both whole animal and fragile heat-treated tissue sections for MALDI MS imaging and quantitation. Journal of Proteomics, 2012, 75, 4912-4920.	1.2	51
92	Ureido-substituted sulfamates show potent carbonic anhydrase IX inhibitory and antiproliferative activities against breast cancer cell lines. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 4681-4685.	1.0	57
93	A model of estrogen-related gene expression reveals non-linear effects in transcriptional response to tamoxifen. BMC Systems Biology, 2012, 6, 138.	3.0	11
94	The Use of Automated Quantitative Analysis to Evaluate Epithelial-to-Mesenchymal Transition Associated Proteins in Clear Cell Renal Cell Carcinoma. PLoS ONE, 2012, 7, e31557.	1.1	22
95	Diversity of Matriptase Expression Level and Function in Breast Cancer. PLoS ONE, 2012, 7, e34182.	1.1	21
96	Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition. Cellular Signalling, 2012, 24, 493-504.	1.7	16
97	Model-based global sensitivity analysis as applied to identification of anti-cancer drug targets and biomarkers of drug resistance in the ErbB2/3 network. European Journal of Pharmaceutical Sciences, 2012, 46, 244-258.	1.9	35
98	Determining tamoxifen sensitivity using primary breast cancer tissue in collagen-based three-dimensional culture. Biomaterials, 2012, 33, 907-915.	5.7	22
99	Targeting of Rac GTPases blocks the spread of intact human breast cancer. Oncotarget, 2012, 3, 608-619.	0.8	57
100	Qualitative and Quantitative MALDI Imaging of the Positron Emission Tomography Ligands Raclopride (a D2 Dopamine Antagonist) and SCH 23390 (a D1 Dopamine Antagonist) in Rat Brain Tissue Sections Using a Solvent-Free Dry Matrix Application Method. Analytical Chemistry, 2011, 83, 9694-9701.	3.2	86
101	What can molecular pathology contribute to the management of renal cell carcinoma?. Nature Reviews Urology, 2011, 8, 255-265.	1.9	66
102	Phosphoprotein pathway profiling of ovarian carcinoma for the identification of potential new targets for therapy. European Journal of Cancer, 2011, 47, 1420-1431.	1.3	18
103	Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence. Journal of Visualized Experiments, 2011, , e3334.	0.2	19
104	An Analytical Approach Differentiates Between Individual and Collective Cancer Invasion. Analytical Cellular Pathology, 2011, 34, 35-48.	0.7	9
105	Sprouty 2 Is an Independent Prognostic Factor in Breast Cancer and May Be Useful in Stratifying Patients for Trastuzumab Therapy. PLoS ONE, 2011, 6, e23772.	1.1	43
106	Long-term Culture of Human Breast Cancer Specimens and Their Analysis Using Optical Projection Tomography. Journal of Visualized Experiments, 2011, , .	0.2	7
107	Routinely Obtained Diagnostic Material as a Source of RNA for Personalized Medicine in Lung Cancer Patients. Journal of Thoracic Oncology, 2011, 6, 884-888.	0.5	5
108	Compensatory effects in the PI3K/PTEN/AKT signaling network following receptor tyrosine kinase inhibition. Cellular Signalling, 2011, 23, 407-416.	1.7	19

#	Article	IF	Citations
109	Two possible mechanisms of epithelial to mesenchymal transition in invasive ductal breast cancer. Clinical and Experimental Metastasis, 2011, 28, 811-818.	1.7	24
110	Utilizing mRNA extracted from small, archival formalin-fixed paraffin-embedded prostate samples for translational research: assessment of the effect of increasing sample age and storage temperature. International Urology and Nephrology, 2011, 43, 961-967.	0.6	6
111	GnRH receptor activation competes at a low level with growth signaling in stably transfected human breast cell lines. BMC Cancer, 2011, 11, 476.	1.1	12
112	Matrixâ€free mass spectrometric imaging using laser desorption ionisation F ourier transform ion cyclotron resonance mass spectrometry. Rapid Communications in Mass Spectrometry, 2011, 25, 969-972.	0.7	26
113	Trastuzumab and Pertuzumab Produce Changes in Morphology and Estrogen Receptor Signaling in Ovarian Cancer Xenografts Revealing New Treatment Strategies. Clinical Cancer Research, 2011, 17, 4451-4461.	3.2	56
114	Transcriptionally repressed genes become aberrantly methylated and distinguish tumors of different lineages in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 4364-4369.	3.3	144
115	Apoptosis and DNA Methylation. Cancers, 2011, 3, 1798-1820.	1.7	25
116	An In Vitro Model That Recapitulates the Epithelial to Mesenchymal Transition (EMT) in Human Breast Cancer. PLoS ONE, 2011, 6, e17083.	1.1	45
117	An analytical approach differentiates between individual and collective cancer invasion. Analytical Cellular Pathology, 2011, 34, 35-48.	0.7	6
118	Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer. Breast Cancer Research, 2010, 12, R39.	2.2	37
119	Prognostic relevance of DNA copy number changes in colorectal cancer. Journal of Pathology, 2010, 220, 338-347.	2.1	48
120	Orphan CpG Islands Identify Numerous Conserved Promoters in the Mammalian Genome. PLoS Genetics, 2010, 6, e1001134.	1.5	445
121	Tyrosine Phosphorylation Profiling Reveals the Signaling Network Characteristics of Basal Breast Cancer Cells. Cancer Research, 2010, 70, 9391-9401.	0.4	165
122	Independent regulation of P53 stabilisation and activation after Rb deletion in primary epithelial cells. International Journal of Oncology, 2010, 37, 31-9.	1.4	2
123	Cancer Systems Biology. Methods in Molecular Biology, 2010, 662, 245-263.	0.4	17
124	Pertuzumab for the treatment of ovarian cancer. Expert Opinion on Biological Therapy, 2010, 10, 1113-1120.	1.4	26
125	Role of CD8+ T lymphocytes in the genesis of angiotensin IIâ€induced hypertension. FASEB Journal, 2010, 24, lb564.	0.2	1
126	Modulation of HER3 Is a Marker of Dynamic Cell Signaling in Ovarian Cancer: Implications for Pertuzumab Sensitivity. Molecular Cancer Research, 2009, 7, 1563-1571.	1.5	38

#	Article	IF	Citations
127	Systems pathologyâ€"taking molecular pathology into a new dimension. Nature Reviews Clinical Oncology, 2009, 6, 455-464.	12.5	62
128	Systems Biology Reveals New Strategies for Personalizing Cancer Medicine and Confirms the Role of PTEN in Resistance to Trastuzumab. Cancer Research, 2009, 69, 6713-6720.	0.4	152
129	WWOX Gene Expression Abolishes Ovarian Cancer Tumorigenicity In vivo and Decreases Attachment to Fibronectin via Integrin Î±3. Cancer Research, 2009, 69, 4835-4842.	0.4	91
130	Attaching and Effacing Escherichia coli Downregulate DNA Mismatch Repair Protein In Vitro and Are Associated with Colorectal Adenocarcinomas in Humans. PLoS ONE, 2009, 4, e5517.	1.1	114
131	How can systems pathology help us personalize cancer therapy?. Discovery Medicine, 2009, 8, 81-6.	0.5	3
132	Effects on kidney disease, fertility and development in mice inheriting a protein-truncating Denys-Drash syndrome allele (Wt1 tmT396). Transgenic Research, 2008, 17, 459-475.	1.3	5
133	Mutationally activated K-ras 4A and 4B both mediate lung carcinogenesis. Experimental Cell Research, 2008, 314, 1105-1114.	1.2	29
134	TGFbeta induces apoptosis and EMT in primary mouse hepatocytes independently of p53, p21 Cip1 or Rbstatus. BMC Cancer, 2008, 8, 191.	1.1	20
135	Truncation of MBD4 predisposes to reciprocal chromosomal translocations and alters the response to therapeutic agents in colon cancer cells. DNA Repair, 2008, 7, 321-328.	1.3	17
136	The tumor suppressor gene DLEC1 is frequently silenced by DNA methylation in hepatocellular carcinoma and induces G1 arrest in cell cycle. Journal of Hepatology, 2008, 48, 433-441.	1.8	51
137	Sensitive, Specific, and Quantitative FTICR Mass Spectrometry of Combinatorial Post-Translational Modifications in Intact Histone H4. Analytical Chemistry, 2008, 80, 4147-4153.	3.2	14
138	Gonadotropin-Releasing Hormone Receptor Levels and Cell Context Affect Tumor Cell Responses to AgonistIn vitroandIn vivo. Cancer Research, 2008, 68, 6331-6340.	0.4	42
139	Differential expression of hDAB2IPA and hDAB2IPB in normal tissues and promoter methylation of hDAB2IPA in hepatocellular carcinoma. Journal of Hepatology, 2007, 46, 655-663.	1.8	54
140	Dynamic computational modeling in the search for better breast cancer drug therapy. Pharmacogenomics, 2007, 8, 1757-1761.	0.6	10
141	Allosteric modulation of beta1 integrin function induces lung repair in animal model of emphysema.. Nature Precedings, 2007, , .	0.1	0
142	Deficiency of G1 regulators P53, P21Cip1and/or pRb decreases hepatocyte sensitivity to TGFÎ² cell cycle arrest. BMC Cancer, 2007, 7, 215.	1.1	23
143	Microarray analysis of gene expression of mouse hepatocytes of different ploidy. Mammalian Genome, 2007, 18, 617-626.	1.0	61
144	Growth factor attenuation of IFNÎ³-mediated hepatocyte apoptosis requires p21wafâ^'1. International Journal of Experimental Pathology, 2006, 87, 275-281.	0.6	4

#	Article	IF	Citations
145	The K-Ras 4A isoform promotes apoptosis but does not affect either lifespan or spontaneous tumor incidence in aging mice. Experimental Cell Research, 2006, 312, 16-26.	1.2	43
146	Improved Retention of Zymogen Granules in Cultured Murine Pancreatic Acinar Cells and Induction of Acinar-Ductal Transdifferentiation In Vitro. Pancreas, 2005, 30, 148-157.	0.5	32
147	p53 deficiency exacerbates pleiotropic mitotic defects, changes in nuclearity and polyploidy in transdifferentiating pancreatic acinar cells. Oncogene, 2005, 24, 2184-2194.	2.6	18
148	Hematopoietic stem cell trafficking in liver injury. FASEB Journal, 2005, 19, 1225-1231.	0.2	101
149	Additive effect of p53, p21 and Rb deletion in triple knockout primary hepatocytes. Oncogene, 2004, 23, 1489-1497.	2.6	33
150	Potential of Hematopoietic Stem Cell Therapy in Hepatology: A Critical Review. Stem Cells, 2004, 22, 897-907.	1.4	58
151	Expression of Sonic hedgehog pathway genes is altered in colonic neoplasia. Journal of Pathology, 2004, 203, 909-917.	2.1	114
152	Functional Smoothened is required for expression of GLI3 in colorectal carcinoma cells. Cancer Letters, 2004, 207, 205-214.	3.2	25
153	Role of oxidative stress in atherosclerosis. American Journal of Cardiology, 2003, 91, 7-11.	0.7	1,073
154	MBD1, MBD2 and CGBP genes at chromosome 18q21 are infrequently mutated in human colon and lung cancers. Oncogene, 2003, 22, 3506-3510.	2.6	31
155	Human cord blood-derived cells can differentiate into hepatocytes in the mouse liver with no evidence of cellular fusion. Gastroenterology, 2003, 124, 1891-1900.	0.6	303
156	While K-ras Is Essential for MouseDevelopment, Expression of the K-ras 4A Splice VariantIsDispensable. Molecular and Cellular Biology, 2003, 23, 9245-9250.	1.1	98
157	Alveolar Epithelial Re-Modelling in Acute Lung Injury. Clinical Science, 2003, 104, 57P-57P.	0.0	0
158	WT1 is a key regulator of podocyte function: reduced expression levels cause crescentic glomerulonephritis and mesangial sclerosis. Human Molecular Genetics, 2002, 11, 651-659.	1.4	241
159	Counting alleles to predict recurrence of early-stage colorectal cancers. Lancet, The, 2002, 359, 219-225.	6.3	140
160	Glutathione and p53 independently mediate responses against oxidative stress in ES cells. Free Radical Biology and Medicine, 2002, 32, 187-196.	1.3	13
161	Functional analysis of mouse hepatocytes differing in DNA content: Volume, receptor expression, and effect of IFN?. Journal of Cellular Physiology, 2002, 191, 138-144.	2.0	40
162	The effect of IFNÎ³ on the hepatocyte: cell cycle and apoptosis. International Journal of Experimental Pathology, 2002, 82, 317-326.	0.6	15

#	Article	IF	Citations
163	Absence of p53 in Clara cells favours multinucleation and loss of cell cycle arrest. BMC Cell Biology, 2002, 3, 27.	3.0	9
164	Carcinogen-induced pancreatic lesions in the mouse: effect of Smad4 and Apc genotypes. Oncogene, 2002, 21, 4696-4701.	2.6	25
165	Phenobarbitone-induced ploidy changes in liver occur independently of p53. Toxicology Letters, 2001, 119, 109-115.	0.4	14
166	To live or die - a cell's choice. Essays in Biochemistry, 2001, 37, 109-120.	2.1	1
167	Inhibition of tumour necrosis factor alpha does not prevent experimental paracetamol-induced hepatic necrosis. , 2000, 190, 489-494.		57
168	Specific patterns of chromosomal abnormalities are associated with RER status in sporadic colorectal cancer. Journal of Pathology, 2000, 192, 440-445.	2.1	29
169	Characterisation of lectin binding patterns of mouse bronchiolar and rat alveolar epithelial cells in culture. The Histochemical Journal, 2000, 32, 33-40.	0.6	16
170	Polymorphisms of the gene for microsomal epoxide hydrolase and susceptibility to alcoholic liver disease and hepatocellular carcinoma in a Caucasian population. Toxicology Letters, 2000, 115, 17-22.	0.4	32
171	A functional, discontinuous HIVâ€‹1 gp120 C3/C4 domainâ€‹derived, branched, synthetic peptide that binds to CD4 and inhibits MIPâ€‹1Î± chemokine binding. FASEB Journal, 1999, 13, 503-511.	0.2	5
172	Dysregulated expression of Î²-catenin marks early neoplastic change in Apc mutant mice, but not all lesions arising in Msh2 deficient mice. Oncogene, 1999, 18, 7219-7225.	2.6	51
173	Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members. Biochemical Journal, 1999, 343, 487-504.	1.7	183
174	p53-independent DNA repair and cell cycle arrest in embryonic stem cells. FEBS Letters, 1998, 425, 499-504.	1.3	47
175	Life and death in the genesis of the tumour cell. Toxicology Letters, 1998, 102-103, 115-119.	0.4	1
176	Hepatitis B x Protein Inhibits p53-dependent DNA Repair in Primary Mouse Hepatocytes. Journal of Biological Chemistry, 1998, 273, 33327-33332.	1.6	76
177	Synthetic peptides representing discontinuous CD4 binding epitopes of HIVâ€‹1 gp120 that induce T cell apoptosis and block cell death induced by gp120. FASEB Journal, 1998, 12, 991-998.	0.2	11
178	Intrahepatic proliferation of â€˜naiveâ€™ and â€˜memoryâ€™ T cells during liver allograft rejection: primary immune response within the allograft. FASEB Journal, 1998, 12, 939-947.	0.2	33
179	Evidence that human class Theta glutathione S-transferase T1-1 can catalyse the activation of dichloromethane, a liver and lung carcinogen in the mouse: Comparison of the tissue distribution of GST T1-1 with that of classes Alpha, Mu and Pi GST in human. Biochemical Journal, 1997, 326, 837-846.	1.7	140
180	Apoptosis: An Overview of the Process and Its Relevance in Disease. Advances in Pharmacology, 1997, 41, 1-34.	1.2	95

#	Article	IF	Citations
181	Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. Lancet, The, 1997, 350, 630-633.	6.3	399
182	p53 deficiency in liver reduces local control of survival and proliferation, but does not affect apoptosis after DNA damage. FASEB Journal, 1997, 11, 591-599.	0.2	81
183	p53, mutation frequency and apoptosis in the murine small intestine. Oncogene, 1997, 14, 2015-2018.	2.6	42
184	Animal models amd the molecular pathology of Cancer. , 1997, 181, 130-135.		7
185	Apoptosis induced by Î³-irradiation, but not CD4 ligation, of peripheral T lymphocytesin vivo is p53-dependent. , 1997, 181, 166-171.		13
186	UV but not Î³-irradiation induces specific transcriptional activity of p53 in primary hepatocytes. , 1997, 183, 177-181.		26
187	Alteration in mRNA levels of Fas splice variants in hepatitis C-infected liver. , 1997, 183, 299-304.		19
188	Alteration in mRNA levels of Fas splice variants in hepatitis C-infected liver. Journal of Pathology, 1997, 183, 299-304.	2.1	1
189	Design and synthesis of a highly immunogenic, discontinuous epitope of HIV-1 gp120 which binds to CD4+ve transfected cells. Molecular Immunology, 1996, 33, 171-178.	1.0	7
190	Induction of Î³-glutamylcysteine synthetase by cigarette smoke is associated with AP-1 in human alveolar epithelial cells. FEBS Letters, 1996, 396, 21-25.	1.3	146
191	Transcriptional Regulation of Î³-Glutamylcysteine Synthetase-Heavy Subunit by Oxidants in Human Alveolar Epithelial Cells. Biochemical and Biophysical Research Communications, 1996, 229, 832-837.	1.0	143
192	Apoptosis in vivo and in vitro: conflict or complementarity?. Trends in Molecular Medicine, 1996, 2, 189-191.	2.6	3
193	The Importance of Apoptosis: is it Real or Imaginary?. Biologicals, 1996, 24, 295-299.	0.5	5
194	High-frequency developmental abnormalities in p53-deficient mice. Current Biology, 1995, 5, 931-936.	1.8	424
195	Cell death in health and disease: the biology and regulation of apoptosis. Seminars in Cancer Biology, 1995, 6, 3-16.	4.3	215
196	The effect of inhibition of glutathione S-transferase P on the growth of the jurkat human T cell line. Journal of Pathology, 1994, 172, 357-362.	2.1	26
197	Lymphocyte Apoptosis - Mechanisms and Implications in Disease. Immunological Reviews, 1994, 142, 141-156.	2.8	32
198	Mice with DNA repair gene (ERCC-1) deficiency have elevated levels of p53, liver nuclear abnormalities and die before weaning. Nature Genetics, 1993, 5, 217-224.	9.4	309

#	Article	IF	Citations
199	Modulation of glutathione S-transferases and glutathione peroxidase by the anticarcinogen butylated hydroxyanisole in murine extrahepatic organs. Carcinogenesis, 1992, 13, 2255-2261.	1.3	21
200	Glutathione s-transferase detoxication enzymes in cervical neoplasia. Journal of Pathology, 1990, 162, 303-308.	2.1	11
201	Glutathione S-transferase localization in aflatoxin B1-treated rat livers. Carcinogenesis, 1990, 11, 927-931.	1.3	15
202	Apoptosis and Cell Senescence. , 0, , 153-192.		3
203	Assessment of clinical trial protocols for pathology content using the <scp>SPIRITâ€Path</scp> guidelines highlights areas for improvement. Journal of Pathology: Clinical Research, 0, , .	1.3	1